

**Supplementary Table . Characteristics of patients who received and did not receive HSCT**

		HSCT (+) n=15	HSCT(-) n=17	P
<b>Sex</b>	Male	<b>11</b>	<b>8</b>	
	Female	<b>4</b>	<b>9</b>	<b>0.131</b>
<b>Age, Y</b>	Median	<b>38</b>	<b>50</b>	<b>0.010</b>
	>65 (%)	<b>0</b>	<b>29</b>	<b>0.045</b>
<b>WBC count×10<sup>9</sup>/mL</b>	Median	<b>23100</b>	<b>51500</b>	<b>0.763</b>
	>30×10 <sup>9</sup> /mL (%)	<b>46</b>	<b>64</b>	<b>0.305</b>
<b>PB blasts, %</b>		<b>69.5</b>	<b>79</b>	<b>0.880</b>
<b>BM blasts, %</b>		<b>95.4</b>	<b>90.2</b>	<b>0.126</b>
<b>LDH IU/L</b>		<b>746</b>	<b>876</b>	<b>0.553</b>
<b>Surface marker</b>	T	<b>3</b>	<b>4</b>	
	B	<b>12</b>	<b>13</b>	<b>0.810</b>
<b>Cytogenetics</b>	Normal	<b>9</b>	<b>3</b>	<b>0.050</b>
	Ph1	<b>5</b>	<b>8</b>	<b>0.543</b>
	Others	<b>1</b>	<b>6</b>	<b>0.084</b>
<b>T-ALL(n=7)</b>				
<b>NOTCH1 status</b>	WT	<b>1</b>	<b>1</b>	
	Mutated	<b>2</b>	<b>3</b>	<b>0.809</b>
<b>MIR9 expression</b>	+	<b>3</b>	<b>3</b>	
	-	<b>12</b>	<b>14</b>	<b>0.865</b>
<b>response to 1st induction therapy</b>	CR	<b>13</b>	<b>12</b>	
	Non-CR	<b>2</b>	<b>5</b>	
<b>RFS</b>	Median (Range)	<b>316 (92-1415)</b>	<b>256 (131-464)</b>	<b>0.437</b>
<b>OS</b>	Median (Range)	<b>1055 (222-3333)</b>	<b>474 (10-3537)</b>	<b>0.007</b>

RFS, relapse-free survival; OS, overall survival.